Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Eleva secures production capacity at 3PBIOVIAN for the clinical-grade material needed to advance its current pipeline programs.
February 4, 2025
By: Charlie Sternberg
Associate Editor, Contract Pharma
Eleva, a pioneer in unlocking biologics based on a breakthrough manufacturing platform, and 3PBIOVIAN, a contract development and manufacturing organization (CDMO), have partnered to collaborate on the manufacturing of current pipeline programs and potential future programs based on Eleva’s technology platform.
Under the terms of the agreement, Eleva secures production capacity at 3PBIOVIAN for the clinical-grade material needed to advance its current pipeline programs into mid- to late-stage clinical development. This covers Factor H (CPV-104), a novel complement modulator currently being developed in C3 Glomerulopathy (C3G) and dry age-related macular degeneration (dry AMD). Additionally, 3PBIOVIAN acquires a non-exclusive license to Eleva’s expression system. As a result of the alliance, Eleva essentially triples its offering of GMP production capacity for programs based on its technology platform.
“With 3PBIOVIAN, we have secured a renowned and high-quality manufacturing partner to support our pipeline expansion strategy. As our current programs advance towards and through clinical studies, forward-looking planning of production capacity is a crucial success factor,” commented Dr. Andreas Schaaf, Ph.D., CSO & Managing Director of Eleva. “At the same time, a range of therapeutic opportunities in our industry could benefit immensely from our moss-based expression system. The relationship with 3PBIOVIAN will allow us to increase the visibility and market penetration of our platform and offers an integrated solution to advance new programs swiftly towards clinical development.”
Dámaso Molero Sánchez, Group CEO at 3PBIOVIAN, added: “We are delighted that Eleva has selected us as a partner for the manufacturing of clinical material for their current pipeline programs, including their novel complement regulator Factor H (CPV-104), which could provide patients with a much-needed new therapeutic option. Access to Eleva’s expression system also supports our commitment to meet the evolving needs of biopharmaceutical developers by continuously expanding our capabilities. Moss-based expression adds a valuable new dimension to our established high-quality offerings in biologics manufacturing.”
Eleva is currently developing Factor H (CPV-104), a recombinant version of human complement Factor H, for complement-related disorders, including CG3 as the first indication, and dry AMD. In C3G, the company expects to enter a Phase 1 clinical study in H1 2025. The clinical material for the first study has already been secured previously. Eleva’s second pipeline program aGal (RPV-001), is being developed in Fabry disease and has delivered promising clinical data in a phase 1b study.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !